Xeris Biopharma Holdings, Inc. provided revenue guidance for the full year 2023. For the year, the company tightens its 2023 guidance by raising the low end of the total revenue range to $145 million - $165 million from $135 to $165 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.765 USD | +0.86% | -1.69% | -25.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.53% | 259M | |
+34.63% | 664B | |
+28.36% | 567B | |
-6.84% | 354B | |
+19.71% | 330B | |
+4.04% | 286B | |
+13.36% | 234B | |
+4.78% | 199B | |
-10.39% | 196B | |
-4.81% | 148B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2023